Review article: Physical and psychological comorbidities associated with irritable bowel syndrome

Shiha, Mohamed G.; Aziz, Imran

doi:10.1111/apt.16589

Cited by 29 publications

(43 citation statements)

References 160 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…26 On the other hand, patients with chronic fatigue syndrome have a 35-92% prevalence of IBS. 18,27 Fibromyalgia was associated with a 1.54-fold increased risk of having IBS according to a national database, 19 whereas a review showed that 32% of women with fibromyalgia had IBS. 18 Up to 40% of patients with chronic pelvic pain fulfilled diagnostic criteria for IBS, and patients with migraine had IBS twice as often than those without migraine.…”

Section: Extraintestinal Manifestationsmentioning

confidence: 99%

“…18 Up to 40% of patients with chronic pelvic pain fulfilled diagnostic criteria for IBS, and patients with migraine had IBS twice as often than those without migraine. [17][18][19] Patients with endometriosis have a two-to three-fold increased risk of IBS compared with controls and patients with interstitial cystitis have an 11-fold increased risk to have IBS compared with controls. 19 About half of the patients with sexual dysfunction also suffered from IBS.…”

Section: Extraintestinal Manifestationsmentioning

confidence: 99%

See 1 more Smart Citation

Extraintestinal manifestations in irritable bowel syndrome: A systematic review

Ohlsson

2022

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Background: Irritable bowel syndrome (IBS) is characterized by abdominal pain and altered bowel habits. Further, IBS patients experience a high degree of extraintestinal symptoms. Objectives: The aim of this review was to describe the relation between IBS and extraintestinal manifestations and mechanisms and treatments of these extraintestinal manifestations. Design: The study was performed as a systematic review. Data Sources and Methods: Search terms including extraintestinal manifestations or somatization and IBS were used to scrutinize for publications in Pubmed. In total, 630 publications were identified and 80 were finally included in this review. Results: About 50% of all IBS patients have extraintestinal manifestations in addition to gastrointestinal symptoms. Somatic pain, fatigue, and sleeping disturbances are most common, and most often described in women. Both extraintestinal manifestations and psychological distress are associated with exaggerated gastrointestinal symptoms, impaired quality of life, and difficulties to treat IBS symptoms. The extraintestinal manifestations render an excess of healthcare costs. Varying etiology and pathophysiology to IBS are discussed, and many patients express a general hypersensitivity. Extraintestinal symptoms are seldom documented at clinical healthcare or included in the assessment of treatment outcomes. A good patient-physician relationship and strengthening of coping mechanisms have rendered less gastrointestinal symptoms, psychological distress, and somatization. Altered lifestyle habits may improve both gastrointestinal and extraintestinal symptoms. Pharmacological treatment, including antidepressant drugs, should be considered when lifestyle advice fails. Teamwork between different specialists and healthcare providers may be of importance in the wide range of symptoms and extraintestinal manifestations. Conclusion: Extraintestinal manifestations are common in IBS patients and is associated with worse suffering and difficulties to treat symptoms. Evaluation and treatment of IBS patients should consider also extraintestinal manifestations and their treatment outcome. Establishment of good relationship, strengthening of coping mechanisms, and education in healthier lifestyle habits are crucial in the management of these patients.

show abstract

Section: Extraintestinal Manifestationsmentioning

confidence: 99%

Section: Extraintestinal Manifestationsmentioning

confidence: 99%

Extraintestinal manifestations in irritable bowel syndrome: A systematic review

Ohlsson

2022

Therap Adv Gastroenterol

View full text Add to dashboard Cite

show abstract

“…Awareness of comorbidities may help guide management decisions and may lead to a multidisciplinary approach to best address all physical and psychological comorbidities [26]. Establishing a diagnosis of IBS-D is important for patient reassurance and to minimize undue cost to the patient or health care system [26]. Given the symptom overlap between IBS-D and other disorders often encountered in primary care practices, consideration of other conditions can guide clinicians (Table 1) [20,[27][28][29][30][31][32][33][34][35][36][37][38][39].…”

Section: Comorbid Disorders: Testing To Exclude Ibsmentioning

confidence: 99%

“…Comorbid conditions are common in patients with IBS and can include anxiety and depression, chronic fatigue, fibromyalgia, and sleep disorders [ 25 , 26 ]. Awareness of comorbidities may help guide management decisions and may lead to a multidisciplinary approach to best address all physical and psychological comorbidities [ 26 ]. Establishing a diagnosis of IBS-D is important for patient reassurance and to minimize undue cost to the patient or health care system [ 26 ].…”

Section: Comorbid Disorders: Testing To Exclude Ibsmentioning

confidence: 99%

A Narrative Review of Irritable Bowel Syndrome with Diarrhea: A Primer for Primary Care Providers

2022

View full text Add to dashboard Cite

Irritable bowel syndrome with diarrhea (IBS-D) is a chronic disorder of gut-brain interaction, characterized by recurrent abdominal pain in association with more frequent, loose stools. The pathophysiology of irritable bowel syndrome (IBS) includes disordered gut motility, alterations in gut microbiota, neural-hormonal system abnormalities, immune reactivity, and visceral hypersensitivity. Timely diagnosis of IBS-D can be achieved easily using clinical criteria. Formal IBS diagnosis is important for optimizing treatment and patient outcomes and facilitating patient access to appropriate educational resources. Yet, given the symptom overlap with other gastrointestinal conditions, diagnosis of IBS-D often is perceived to be challenging. Treatment of IBS includes both nonpharmacologic and pharmacologic options. Rifaximin, alosetron, and eluxadoline are effective treatments indicated for IBS-D, but have limited availability internationally. Dietary approaches may also be indicated for certain patients with IBS-D. Psychological interventions may be effective in treating abdominal pain alone and global symptoms in IBS. We describe use of these diverse therapies and provide an overview to facilitate the primary care provider's approach to distinguishing IBS-D from other conditions with symptom overlap.

show abstract

“…Irritable bowel syndrome (IBS) is a disorder of gut-brain interaction (DGBI) that affects approximately 4% of the global population but estimates vary based on nonuniform study methodology [ 1 ]. Patients with IBS often display symptoms such as altered stool forms, constipation, bloating, and abdominal pain with overlapping co-morbidities including depression, anxiety, chronic fatigue, insomnia, sexual dysfunction, and fibromyalgia, collectively impairing quality of life [ 2 , 3 ]. A 2013 systematic review estimated the direct and indirect health care costs of IBS to be between $22–30 billion [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Identification of putative transcriptomic biomarkers in irritable bowel syndrome (IBS): Differential gene expression and regulation of TPH1 and SERT by vitamin D

Grozić

Coker²,

Dussik³

et al. 2022

PLoS ONE

View full text Add to dashboard Cite

Irritable bowel syndrome (IBS) is one of the most common gastrointestinal disorders and affects approximately 4% of the global population. The diagnosis of IBS can be made based on symptoms using the validated Rome criteria and ruling out commonly occurring organic diseases. Although biomarkers exist for “IBS mimickers” such as celiac disease and inflammatory bowel disease (IBD), no such test exists for IBS. DNA microarrays of colonic tissue have been used to identify disease-associated variants in other gastrointestinal (GI) disorders. In this study, our objective was to identify biomarkers and unique gene expression patterns that may define the pathological state of IBS. Mucosal tissue samples were collected from the sigmoid colon of 29 participants (11 IBS and 18 healthy controls). DNA microarray analysis was used to assess gene expression profiling. Extraction and purification of RNA were then performed and used to synthesize cDNA. Reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) was employed to identify differentially expressed genes in patients diagnosed with IBS compared to healthy, non-IBS patient-derived cDNA. Additional testing probed vitamin D-mediated regulation of select genes associated with serotonergic metabolism. DNA microarray analyses led to the identification of 858 differentially expressed genes that may characterize the IBS pathological state. After screening a series of genes using a combination of gene ontological analysis and RT-qPCR, this spectrum of potential IBS biomarkers was narrowed to 23 genes, some of which are regulated by vitamin D. Seven putative IBS biomarkers, including genes involved in serotonin metabolism, were identified. This work further supports the hypothesis that IBS pathophysiology is evident within the human transcriptome and that vitamin D modulates differential expression of genes in IBS patients. This suggests that IBS pathophysiology may also involve vitamin D deficiency and/or an irregularity in serotonin metabolism.

show abstract

Review article: Physical and psychological comorbidities associated with irritable bowel syndrome

Cited by 29 publications

References 160 publications

Extraintestinal manifestations in irritable bowel syndrome: A systematic review

Extraintestinal manifestations in irritable bowel syndrome: A systematic review

A Narrative Review of Irritable Bowel Syndrome with Diarrhea: A Primer for Primary Care Providers

Identification of putative transcriptomic biomarkers in irritable bowel syndrome (IBS): Differential gene expression and regulation of TPH1 and SERT by vitamin D

Contact Info

Product

Resources

About